SnapShot: Cancer Immunotherapy with Oncolytic Viruses
暂无分享,去创建一个
[1] J. Allison,et al. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. , 2018, Cancer discovery.
[2] S. Gujar,et al. Potentiating prostate cancer immunotherapy with oncolytic viruses , 2018, Nature Reviews Urology.
[3] Lucy F. Stead,et al. Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade , 2018, Science Translational Medicine.
[4] J. Diallo,et al. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy , 2018, Science Translational Medicine.
[5] G. Kroemer,et al. Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies. , 2017, Trends in immunology.
[6] J. Wolchok,et al. Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy , 2014, Science Translational Medicine.
[7] J. Diallo,et al. From Scourge to Cure: Tumour-Selective Viral Pathogenesis as a New Strategy against Cancer , 2014, PLoS pathogens.
[8] H. Atkins,et al. A High-throughput Pharmacoviral Approach Identifies Novel Oncolytic Virus Sensitizers. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[9] A. García-Sastre,et al. Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.